静脉注射皮质类固醇冲击是否优于小剂量皮质类固醇治疗重症 COVID-19 患者？
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?
机构信息
BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
BRICNet - Brazilian Research in Intensive Care Network, Brazil.
出版信息
Eur Respir J. 2022 Oct 20;60(4). doi: 10.1183/13993003.01220-2022. Print 2022 Oct.
Corticosteroids were the first drugs proven to reduce mortality in Covid-19. In June 2020, the RECOVERY group announced the results of their seminal trial showing dexamethasone 6 mg per day was able to reduce 28-day mortality in hospitalized patients with Covid needing supplemental oxygen or mechanical ventilation [1]. Meta-analysis from randomized controlled trials (RCT) in Covid-19 patients confirmed RECOVERY results [2]. In those RCTs, corticosteroid doses were low (dexamethasone 6 mg per day) or intermediate (dexamethasone up to 20mg per day).
皮质类固醇是第一批被证明能降低新冠死亡率的药物。2020 年 6 月，RECOVERY 研究组公布了他们的重要试验结果，表明每天给予 6mg 地塞米松可降低需要补充氧气或机械通气的住院新冠患者 28 天死亡率[1]。针对新冠患者的随机对照试验（RCT）的荟萃分析证实了 RECOVERY 研究的结果[2]。在这些 RCT 中，皮质类固醇的剂量较低（地塞米松每天 6mg）或中等（地塞米松每天高达 20mg）。
Zotero 插件